Lyell Immunopharma Income Statement (2019-2025) | LYEL

1Y3Y5Y7Y10YAll
Download Data
Income Statement Dec2019 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 1.26M1.07M2.31M2.44M2.63M2.75M2.82M0.55M35.74M0.00M48.39M0.07M0.03M0.03M0.01M0.00M0.01M0.03M0.01M0.01M0.01M0.01M
Operating items
Research & Development 25.50M24.50M35.09M41.53M46.45M31.43M19.29M35.83M43.72M41.61M38.03M44.63M47.47M43.85M46.99M43.17M40.26M39.50M48.67M43.45M34.86M28.17M
Selling, General & Administrative 8.88M13.57M14.87M16.83M19.11M21.24M31.87M34.42M30.45M26.08M26.35M19.28M19.03M15.51M13.17M13.49M12.26M11.77M14.52M14.05M9.79M10.69M
Other Operating Expenses 0.12M0.16M8.12M0.55M0.22M0.76M0.80M1.12M1.17M1.25M1.21M1.29M0.57M0.29M0.64M1.09M0.98M0.73M0.51M0.12M-1.06M1.59M
Operating Expenses 34.26M37.91M41.84M57.81M65.33M51.92M50.36M69.13M73.00M66.44M63.17M62.62M65.93M59.06M59.52M55.58M51.54M50.54M201.16M57.37M47.15M37.27M
Operating Income -33.00M-36.84M-39.52M-55.37M-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M
EBIT -33.00M-36.84M-39.52M-55.37M-62.71M-49.16M-47.54M-68.58M-37.26M-66.44M-14.78M-62.56M-65.91M-59.04M-59.51M-55.58M-51.53M-50.51M-201.15M-57.37M-47.14M-37.25M
Non-operating items
Interest & Investment Income 2.34M1.10M0.62M0.35M0.22M0.27M0.32M0.40M0.95M2.25M3.45M4.50M5.26M6.61M7.08M6.82M6.36M5.96M4.92M3.86M3.28M3.27M
Other Non Operating Income 1.42M0.03M0.05M-0.03M-0.11M0.02M-0.04M0.04M-0.01M-1.07M2.93M1.10M-0.33M1.58M-0.51M1.09M-0.65M-0.04M4.29M1.31M1.18M-4.86M
Non Operating Income 1.42M0.03M5.99M0.33M0.11M0.29M-36.17M0.43M0.94M-3.82M6.39M-4.40M2.02M8.19M6.58M-5.09M5.72M5.92M9.21M5.17M4.46M-4.86M
Net income details
EBT -30.66M-35.75M-38.90M-55.02M-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M
Profit After Tax -29.24M-35.72M-38.86M-55.04M-62.59M-48.88M-83.71M-68.14M-36.32M-70.25M-8.40M-66.96M-63.89M-50.85M-52.93M-60.67M-45.81M-44.58M-191.94M-52.20M-42.68M-38.85M
Income from Continuing Operations -30.66M-35.75M-38.90M-55.02M-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M
Consolidated Net Income -30.66M-35.75M-38.90M-55.02M-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M
Income towards Parent Company -30.66M-35.75M-38.90M-55.02M-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M
Net Income towards Common Stockholders -30.66M-35.75M-38.90M-55.02M-62.49M-48.89M-47.22M-68.18M-36.31M-64.19M-11.33M-58.06M-60.64M-52.43M-52.42M-48.76M-45.16M-44.54M-196.23M-53.51M-43.86M-33.99M
Additional items
EPS (Basic) -2.96-2.57-2.29-3.19-1.47-0.20-0.18-0.28-0.15-0.28-0.03-0.27-0.26-0.20-0.20-0.24-3.59-3.4810.52-0.18-2.89-2.13
EPS (Weighted Average and Diluted) -2.93-3.19-1.47-0.20-0.18-0.28-0.15-0.28-0.03-0.27-0.26-0.20-0.20-0.24-3.59-3.4810.52-0.18-2.89-2.13
Shares Outstanding (Weighted Average) 12.14M12.14M11.97M11.97M12.02M12.27M12.31M12.39M12.47M12.48M12.48M12.55M12.70M12.70M12.80M12.80M13.96M14.76M14.77M19.21M
Shares Outstanding (Diluted Average) 0.01M13.26M17.27M42.71M239.38M135.92M244.18M246.31M248.32M247.08M249.59M250.20M251.32M250.98M254.25M12.77M12.81M261.48M295.10M14.79M18.27M
EBITDA -28.61M-36.32M-39.19M-55.14M-62.69M-49.01M-85.26M-73.12M-38.07M-71.90M-6.00M-63.24M-62.39M-49.66M-51.84M-60.98M-45.80M-43.43M-192.40M-52.33M-42.78M-38.70M
Shares Outstanding 11.18M15.57M238.55M239.79M242.74M